AH
Anders Hove Portfolio
Invests via Acorn Capital Advisors LLC | Managed by Anders Hove
Invests via Acorn Capital Advisors LLC
Managed by Anders Hove
Automatically Tracked
Seasoned Scandinavian entrepreneur and investor with operational experience in scaling technology and healthcare businesses. Anders Hove is known for leading growth-stage companies, directing strategic M&A, and allocating capital across early-stage venture and private equity. Focus areas include enterprise software, healthtech and real assets; typical involvement spans board roles, active portfolio management and follow-on financing. Market-minded profile useful for LP introductions, deal sourcing and strategic partnerships.
Seasoned Scandinavian entrepreneur and investor with operational experience in scaling technology and healthcare businesses. Anders Hove is known for leading growth-stage companies, directing strategic M&A, and allocating capital across early-stage venture and private equity. Focus areas include enterprise software, healthtech and real assets; typical involvement spans board roles, active portfolio management and follow-on financing. Market-minded profile useful for LP introductions, deal sourcing and strategic partnerships.
Investment Philosophy & Strategy
Seasoned operator-investor who favors growth-stage, value-creating opportunities at the intersection of enterprise software, healthtech and real assets. Deploys capital with a hands-on, board-active approach, prioritizing companies with repeatable unit economics, clear M&A optionality and measurable path to profitability. Time horizon is medium-to-long; risk discipline combines staged financings, follow-on reserves and strategic partnerships to accelerate exits and protect downside.
Seasoned operator-investor who favors growth-stage, value-creating opportunities at the intersection of enterprise software, healthtech and real assets. Deploys capital with a hands-on, board-active approach, prioritizing companies with repeatable unit economics, clear M&A optionality and measurable path to profitability. Time horizon is medium-to-long; risk discipline combines staged financings, follow-on reserves and strategic partnerships to accelerate exits and protect downside.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
-6.78%
Gain
Monthly
-0.38%
Yearly
-4.45%
Drawdown
59.51%
$433.08M
Equity
Holdings
$433.08M
Investment
$201.53M
$219.15M
Profit +$75.96M
Realized
-$12.4M
Unrealized
$231.55M
Dividends
$0
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
0%
Profit
$75.96M
Win %
63%
This Week
Compared To Last Week
Gain
22.08%
Profit
$78.31M
Win %
63%
This Month
Compared to last month
Gain
3.94%
Profit
$16.41M
Win %
63%
This Year
Compared to last year
Gain
23.1%
Profit
$81.25M
Win %
58%
TRVI Trevi Therapeutics Inc.
+13.39%
+$4.99M 
CADL Candel Therapeutics Inc.
+8.54%
+$2.83M 
CGON CG Oncology, Inc.
+4.04%
+$3.17M 
URGN Urogen Pharma Ltd.
+3.4%
+$2.27M 
JBIO Jade Biosciences Inc.
+2.93%
+$472,056 
HELP Cybin Inc.
+2.27%
+$246,442.56 
PBYI Puma Biotechnology Inc.
+2.26%
+$784,946.81 
CRDF Cardiff Oncology Inc.
+2.1%
+$32,422.35 
WHWK Whitehawk Therapeutics, Inc.
+1.8%
+$79,755.41 
BCAX Bicara Therapeutics Inc.
+1.79%
+$318,474.09 
QTTB Q32 Bio Inc.
+1.51%
+$72,461.96 
BCAB BioAtla, Inc.
+1.5%
+$6,487.61 
AURA Aura Biosciences Inc.
+1.15%
+$47,004.2 
TARA Protara Therapeutics Inc.
+1.1%
+$78,845.18 
KPTI Karyopharm Therapeutics Inc.
+0.8%
+$21,586.95 
VYNE Vyne Therapeutics Inc.
+0.31%
+$3.42 
VSTM Verastem Inc.
+0.09%
+$7,345.77 
TERN Terns Pharmaceuticals, Inc.
0%
$0 
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 70 | Longs Won 34/70 48% | Profit Factor 6.43 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $11.15M |
| Average Win $7.63M | Best Trade (Jul 10) $60.87M | Sharpe Ratio -9.63 |
| Average Loss -$1.12M | Worst Trade (Sep 29) -$9.5M | Z-Score 1.33 (81.73%) |
| Commissions $0 | Avg. Trade Length 11m 2w 2d | Expectancy $3.13M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 386 | 347 | 309 | 270 | 232 | 193 | 154 | 116 | 77 | 39 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
